Oleksandr Siedov The UK government has reached agreement with the US government that drugs made in the UK will not face tariffs in the US. Medicines exported from Britain will have a tariff exemption for a minimum of three years. While the deal was first brokered in December, the UK did not agree to the full text of it until Thursday. Terms include having the UK increase the cost-effectiveness thr...
Oleksandr Siedov The UK government has reached agreement with the US government that drugs made in the UK will not face tariffs in the US. Medicines exported from Britain will have a tariff exemption for a minimum of three years. While the deal was first brokered in December, the UK did not agree to the full text of it until Thursday. Terms include having the UK increase the cost-effectiveness threshold used by its National Institute for Health and Care Excellence ("NICE") by 25%. Also, the maximum rebate the National Health Service can get from pharma companies is 15%. In addition, the NHS will pay 25% higher list prices for new prescription drugs. Medtech products that are exported are also free from tariffs for at least the next three years. The UK will also boost spending on drug R&D to 0.6% from 0.3% of GDP. UK pharma exports to the US stand at more than £5B (~$6.6B) annually. More on GSK, AstraZeneca GSK: Chinese Expansion And Fine Financials GSK plc (GSK) Presents at Goldman Sachs 9th Annual Biopharma Innovation Summit Transcript AstraZeneca: The Big China Bet Astra posts late-stage trial win for Imfinzi regimen in liver cancer Former CDC advisor says White House pulling back on vaccine policy
Alphabet (NasdaqGS:GOOGL) has introduced Veo 3.1 Lite, a lower cost, high volume AI video generation model. The company is also cutting prices on its Veo 3.1 Fast tier, targeting developers and enterprises with large scale video needs. These moves follow OpenAI’s decision to discontinue its Sora video product, reshaping competition in AI video tools. Alphabet, through Google Cloud and its broader ...
Alphabet (NasdaqGS:GOOGL) has introduced Veo 3.1 Lite, a lower cost, high volume AI video generation model. The company is also cutting prices on its Veo 3.1 Fast tier, targeting developers and enterprises with large scale video needs. These moves follow OpenAI’s decision to discontinue its Sora video product, reshaping competition in AI video tools. Alphabet, through Google Cloud and its broader AI portfolio, is pushing deeper into video generation tools that can plug into content...
There's been a lot of public is concerned about health risks from the chemicals, especially from the Make America Healthy Again movement. The agency's move doesn't in itself guarantee regulation. (Image credit: Justin Sullivan)
There's been a lot of public is concerned about health risks from the chemicals, especially from the Make America Healthy Again movement. The agency's move doesn't in itself guarantee regulation. (Image credit: Justin Sullivan)
To be honest, I thought Elon Musk would confidentially file for SpaceX's IPO on the 20th of this month, rather than the 1st. But maybe that just means he's moved on to other numbers, and we should all mark our calendars for June 7th as an IPO date just in case. Based on the April 1st filing, and the general length of an SEC review before the S-1 document becomes public, the earliest I am expecting...
To be honest, I thought Elon Musk would confidentially file for SpaceX's IPO on the 20th of this month, rather than the 1st. But maybe that just means he's moved on to other numbers, and we should all mark our calendars for June 7th as an IPO date just in case. Based on the April 1st filing, and the general length of an SEC review before the S-1 document becomes public, the earliest I am expecting a SpaceX IPO is June. (At least, assuming there is still anyone left at the SEC who wants to do their job instead of just glance at the first page of the filing, say, "Seems fine!" and then go out for a smoke break.) Of course, this process could … Read the full story at The Verge.
Olga Yastremska/iStock via Getty Images The last time I spoke about Vertex Pharmaceuticals ( VRTX ) it was with a Seeking Alpha article entitled " Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant "Strong Buy ." With respect to this article, I mentioned that the company was seeing strong demand in terms of its drug JOURNAVX [suzetrigine] , approved to treat...
Olga Yastremska/iStock via Getty Images The last time I spoke about Vertex Pharmaceuticals ( VRTX ) it was with a Seeking Alpha article entitled " Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant "Strong Buy ." With respect to this article, I mentioned that the company was seeing strong demand in terms of its drug JOURNAVX [suzetrigine] , approved to treat patients with moderate-to-severe acute pain. That, plus it was in the process of exploring the use of this drug in two ongoing phase 3 studies targeting patients with diabetic peripheral neuropathy [DPN] as well. It will continue to enroll patients for this program through 2026. For the 12 months ending December 31, 2025, it generated approximately $59.6 million in revenues from it. What I also went over was the fact that this company was in the process of advancing its BAFF/APRIL inhibitor povetacicept for the treatment of patients with Immunoglobulin A Nephropathy [IgAN] and Primary Membranous Neuropathy [PMN]. Speaking of which, as an update, it was noted that the company released positive results from a pre-specified 36-week interim analysis from the phase 3 RAINER study using povetacicept on top of standard of care [SOC] to treat these patients with IgAN. In essence, there was a statistically significant and clinically meaningful 49.8% urine protein to creatinine ratio [UPCR] reduction compared to placebo. This clinical effect was statistically significant with a p-value of p<0.0001. The point here is that the company already submitted several modules of its Biologics License Application [BLA] of povetacicept for the treatment of patients with IgAN. The expected completion for full submission was set by the end of March of 2026. The point here is that the company is vying for potential FDA Accelerated Approval of this BLA of this drug for these patients. Even better, it is expected to use a priority review voucher [PRV] to speed up the review of it from 10 months to 6...
The State Street Consumer Staples Select Sector SPDR ETF (NYSEMKT:XLP) and the Invesco Food & Beverage ETF (NYSEMKT:PBJ) both deliver exposure to U.S. consumer staples, but with a few notable differences. XLP charges lower fees, yields more, and aims for broad, low-cost coverage of the consumer staples sector -- while PBJ zeroes in on food and beverage companies. Beta measures price volatility rel...
The State Street Consumer Staples Select Sector SPDR ETF (NYSEMKT:XLP) and the Invesco Food & Beverage ETF (NYSEMKT:PBJ) both deliver exposure to U.S. consumer staples, but with a few notable differences. XLP charges lower fees, yields more, and aims for broad, low-cost coverage of the consumer staples sector -- while PBJ zeroes in on food and beverage companies. Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Continue reading
saifulasmee chede/iStock via Getty Images I have followed Tilray Brands ( TLRY ) closely since it went public in 2018. I never really liked the stock until 2025. Most recently, I was negative on it again, sharing in early December that it was no longer a Strong Sell and rating it Hold. The company just reported its fiscal Q3 on April 1, and I am maintaining a Hold for now. FY26 So Far for Tilray B...
saifulasmee chede/iStock via Getty Images I have followed Tilray Brands ( TLRY ) closely since it went public in 2018. I never really liked the stock until 2025. Most recently, I was negative on it again, sharing in early December that it was no longer a Strong Sell and rating it Hold. The company just reported its fiscal Q3 on April 1, and I am maintaining a Hold for now. FY26 So Far for Tilray Brands Tilray reported its fiscal Q3 on April 1, and it was no joke. The company headlined the " record results " it experienced with its revenue, but it was not so pretty. Overall revenue did increase sequentially to $206.7 million, which was up 11% from Q3 a year ago, but there were areas of strength and weakness. Distribution revenue grew 35% to $83.0 million. Cannabis revenue was the second-largest of the four segments, and net revenue rose 24% to $64.8 million. The Beverage business was quite weak, with net alcohol sales falling 24% to $42.6 million. The smallest business, Wellness (hemp products), grew 16% to $16.4 million. Through three quarters of fiscal 2026, overall revenue has grown just 6%, with Distribution (European pharmaceuticals) at $242.3 million, up 23%. Cannabis, the second-largest at $196.9 million, has been up 9%. Beverages have declined 15% to $148.4 million. Wellness has increased 6% to $46.2 million. The weakness in alcohol sales comes after several acquisitions, and, according to the 10-Q, consumers are drinking fewer drinks with alcohol. Tilray Brands does sell non-alcoholic beer and other beverages that have no alcohol. The strength in cannabis is due to market share gains in Canada and rapid international expansion. TLRY claims to be the largest provider of medical cannabis in Germany, and it operates in several medical cannabis markets. The gain in revenue in the Distribution business has come from a price increase (13% in Q3 and 4% year-to-date) and a volume increase (7% in Q3 and 11% year-to-date). Tilray Brands provides gross margins for each...
For years, cryptocurrency supporters have argued that it was the future of money. Thanks to artificial intelligence (AI), that future is becoming a reality. OpenClaw, an open-source AI assistant program, helped put AI agents on the map when it went viral earlier this year. AI agents can browse the web, use programs, and make purchases -- all autonomously. Many AI agents have begun transacting on S...
For years, cryptocurrency supporters have argued that it was the future of money. Thanks to artificial intelligence (AI), that future is becoming a reality. OpenClaw, an open-source AI assistant program, helped put AI agents on the map when it went viral earlier this year. AI agents can browse the web, use programs, and make purchases -- all autonomously. Many AI agents have begun transacting on Solana (CRYPTO: SOL) , a blockchain known for its lightning-fast transaction speeds and low fees. Here is how AI agents could make Solana a must-have cryptocurrency for the future. Continue reading
OpenAI CEO Sam Altman addresses the gathering at the AI Impact Summit, in New Delhi, India, February 19, 2026. Bhawika Chhabra | Reuters OpenAI announced that it has acquired the technology news podcast TBPN , according to a message shared with employees on Thursday. TBPN is a daily podcast hosted by John Coogan and Jordi Hays that covers technology news and features interviews with major tech lea...
OpenAI CEO Sam Altman addresses the gathering at the AI Impact Summit, in New Delhi, India, February 19, 2026. Bhawika Chhabra | Reuters OpenAI announced that it has acquired the technology news podcast TBPN , according to a message shared with employees on Thursday. TBPN is a daily podcast hosted by John Coogan and Jordi Hays that covers technology news and features interviews with major tech leaders, including Meta CEO Mark Zuckerberg , Microsoft CEO Satya Nadella , and OpenAI co-founder and CEO Sam Altman. The Wall Street Journal was first to report the news. In the announcement, OpenAI CEO of AGI Deployment Fidji Simo wrote that their mission of bringing artificial general intelligence comes with a responsibility to have a space for "constructive conversation about the changes AI creates." OpenAI did not disclose the terms of the deal but said TBPN will be housed within its strategy organization. Read more CNBC tech news SpaceX confidentially files for IPO, setting stage for record offering Five key questions Apple faces entering its second half-century Baidu robotaxis reportedly halted mid-traffic causing crashes in Wuhan, China Iran threatens Nvidia, Apple and other tech giants with attacks "While we've been critical of the industry at times, after getting to know Sam and the OpenAI team, what stood out most was their openness to feedback and commitment to getting this right," wrote Hays in a statement. "Moving from commentary to real impact in how this technology is distributed and understood globally is incredibly important to us." CNBC has reached out to OpenAI for additional comment. TBPN generated about $5 million in advertising revenue in 2025 and is on track to exceed $30 million this year, according to the Wall Street Journal. watch now VIDEO 2:12 02:12 OpenAI opens up to retail as it closes record $122 billion round Closing Bell: Overtime Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news...
Alphabet (NASDAQ:GOOG) continues to be an AI force, even as shares come in due to broader market fears and distaste for hefty CapEx. While it’s easy to start taking some profits off the table on shares of Google as the Magnificent Seven trade continues to fly south, I do think that by doing so, especially ... Google’s TurboQuant Breakthrough Just Rewrote the AI Playbook
Alphabet (NASDAQ:GOOG) continues to be an AI force, even as shares come in due to broader market fears and distaste for hefty CapEx. While it’s easy to start taking some profits off the table on shares of Google as the Magnificent Seven trade continues to fly south, I do think that by doing so, especially ... Google’s TurboQuant Breakthrough Just Rewrote the AI Playbook
May NY world sugar #11 (SBK26 ) today is down -0.23 (-1.50%), and May London ICE white sugar #5 (SWK26 ) is down -3.70 (-0.84%). Sugar prices are falling today, with NY sugar posting a 2-week low. Ramped up sugar production in India is undercutting prices today after India's National...
May NY world sugar #11 (SBK26 ) today is down -0.23 (-1.50%), and May London ICE white sugar #5 (SWK26 ) is down -3.70 (-0.84%). Sugar prices are falling today, with NY sugar posting a 2-week low. Ramped up sugar production in India is undercutting prices today after India's National...
wingedwolf President Trump announced Friday that Pam Bondi is stepping down as U.S. Attorney General for a yet-to-be-named private sector job. "Pam Bondi is a Great American Patriot and a loyal friend, who faithfully served as my Attorney General over the past year. Pam did a tremendous job overseeing a massive crackdown in Crime across our Country, with Murders plummeting to their lowest level si...
wingedwolf President Trump announced Friday that Pam Bondi is stepping down as U.S. Attorney General for a yet-to-be-named private sector job. "Pam Bondi is a Great American Patriot and a loyal friend, who faithfully served as my Attorney General over the past year. Pam did a tremendous job overseeing a massive crackdown in Crime across our Country, with Murders plummeting to their lowest level since 1900," Trump said in a post on Truth Social on Friday afternoon. "We love Pam, and she will be transitioning to a much-needed and important new job in the private sector, to be announced at a date in the near future, and our Deputy Attorney General, and a very talented and respected Legal Mind, Todd Blanche, will step in to serve as Acting Attorney General," Trump added. According to Bloomberg , Trump is considering nominating Environmental Protection Agency Administrator Lee Zeldin as Bondi's successor. Bondi's departure follows months of harsh criticism for her handling of the release of the Justice Department's files on the Jeffrey Epstein sex-trafficking case. More on SPDR S&P 500 ETF Trust, Vanguard 500 Index Fund ETF There Is No Easy Off-Ramp To The Iranian War A Major Market Rotation Is Likely Coming: Here's Where I'm Loading Up Brace For Inflationary Shock: March CPI Preview One year since the tariff shock of Trump's 'liberation day' S&P 500 seen at 7,700 despite tensions, Citi’s Chronert says - CNBC interview